Which imaging modality is most associated with assessing diffusion metrics and microhemorrhages in TBI prognosis?

Which imaging modality is most associated with assessing diffusion metrics and microhemorrhages in TBI prognosis?

• A. X-ray
• B. MRI
• C. Ultrasound
• D. PET

Answer: (B)

In traumatic brain injury prognosis, two classes of imaging biomarkers are particularly informative: diffusion metrics and microhemorrhages. Diffusion metrics come from diffusion-weighted imaging (DWI) and diffusion tensor imaging (DTI) and quantify how water moves in tissue. Changes in diffusion reveal cytotoxic edema and white matter tract integrity; metrics like fractional anisotropy and mean diffusivity reflect axonal injury and network disruption, which strongly relate to outcomes. Microhemorrhages result from small vessel injury and are most clearly seen on susceptibility-sensitive MRI sequences such as SWI or gradient-echo T2*, making MRI crucial for detecting these bleeds that often accompany diffuse axonal injury and worsen prognosis. Other modalities don’t provide this combination of diffusion information and microhemorrhage detection with the same sensitivity. X-ray and ultrasound lack the soft-tissue detail needed to assess brain diffusion and microbleeds. PET contributes metabolic information but not the diffusion metrics or microhemorrhage visualization as MRI does. So MRI stands out as the best choice for evaluating these prognostically relevant imaging features.

In traumatic brain injury prognosis, two classes of imaging biomarkers are particularly informative: diffusion metrics and microhemorrhages. Diffusion metrics come from diffusion-weighted imaging (DWI) and diffusion tensor imaging (DTI) and quantify how water moves in tissue. Changes in diffusion reveal cytotoxic edema and white matter tract integrity; metrics like fractional anisotropy and mean diffusivity reflect axonal injury and network disruption, which strongly relate to outcomes. Microhemorrhages result from small vessel injury and are most clearly seen on susceptibility-sensitive MRI sequences such as SWI or gradient-echo T2*, making MRI crucial for detecting these bleeds that often accompany diffuse axonal injury and worsen prognosis.

Other modalities don’t provide this combination of diffusion information and microhemorrhage detection with the same sensitivity. X-ray and ultrasound lack the soft-tissue detail needed to assess brain diffusion and microbleeds. PET contributes metabolic information but not the diffusion metrics or microhemorrhage visualization as MRI does. So MRI stands out as the best choice for evaluating these prognostically relevant imaging features.